Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 242

1.

Computed Tomography Findings as a Novel Predictor of Alcohol-Associated Hepatitis Outcomes.

Bloom PP, Mojtahed A, Bethea ED, Knooihuizen SA, Choi J, Dienstag JL, Chung RT, Hur C.

Dig Dis Sci. 2019 Jul 30. doi: 10.1007/s10620-019-05721-4. [Epub ahead of print]

PMID:
31363954
2.

Physicians' Perspectives on Palliative Care for Patients With End-Stage Liver Disease: A National Survey Study.

Ufere NN, Donlan J, Waldman L, Patel A, Dienstag JL, Friedman LS, Corey KE, Hashemi N, Carolan P, Mullen AC, Thiim M, Bhan I, Nipp R, Greer J, Temel J, Chung RT, El-Jawahri A.

Liver Transpl. 2019 Jun;25(6):859-869. doi: 10.1002/lt.25469. Epub 2019 May 3.

PMID:
30963669
3.

Barriers to Use of Palliative Care and Advance Care Planning Discussions for Patients With End-Stage Liver Disease.

Ufere NN, Donlan J, Waldman L, Dienstag JL, Friedman LS, Corey KE, Hashemi N, Carolan P, Mullen AC, Thiim M, Bhan I, Nipp R, Greer JA, Temel JS, Chung RT, El-Jawahri A.

Clin Gastroenterol Hepatol. 2019 Mar 15. pii: S1542-3565(19)30286-1. doi: 10.1016/j.cgh.2019.03.022. [Epub ahead of print]

PMID:
30885884
4.

Reply to: "Primed for the spotlight: Transplantation for alcohol-associated liver disease".

Luther J, Dienstag JL.

J Hepatol. 2018 Jul;69(1):255. doi: 10.1016/j.jhep.2018.03.015. Epub 2018 Apr 9. No abstract available.

PMID:
29650334
5.

Hardened Liver Due to Fibrolamellar Hepatocellular Carcinoma.

Luther J, Dienstag JL.

Clin Gastroenterol Hepatol. 2019 Jan;17(1):A27. doi: 10.1016/j.cgh.2018.02.040. Epub 2018 Mar 2. No abstract available.

PMID:
29505903
6.

Reply to: "Assessment of the risk of alcohol relapse following liver transplantation for alcoholic hepatitis using a meta-analysis approach".

Luther J, Dienstag JL.

J Hepatol. 2018 Jun;68(6):1323. doi: 10.1016/j.jhep.2018.02.019. Epub 2018 Mar 2. No abstract available.

PMID:
29505846
7.

Early liver transplantation for alcoholic hepatitis: Ready for primetime?

Kubiliun M, Patel SJ, Hur C, Dienstag JL, Luther J.

J Hepatol. 2018 Mar;68(3):380-382. doi: 10.1016/j.jhep.2017.11.027. Epub 2017 Nov 24. No abstract available.

PMID:
29175244
8.

Prognosis of Patients with Cirrhosis and AKI Who Initiate RRT.

Allegretti AS, Parada XV, Eneanya ND, Gilligan H, Xu D, Zhao S, Dienstag JL, Chung RT, Thadhani RI.

Clin J Am Soc Nephrol. 2018 Jan 6;13(1):16-25. doi: 10.2215/CJN.03610417. Epub 2017 Nov 9.

9.

Academic Performance on First-Year Medical School Exams: How Well Does It Predict Later Performance on Knowledge-Based and Clinical Assessments?

Krupat E, Pelletier SR, Dienstag JL.

Teach Learn Med. 2017 Apr-Jun;29(2):181-187. doi: 10.1080/10401334.2016.1259109. Epub 2017 Jan 18.

PMID:
28098483
10.

Factors associated with physicians' choice of a career in research: a retrospective report 15 years after medical school graduation.

Krupat E, Camargo CA Jr, Strewler GJ, Espinola JA, Fleenor TJ Jr, Dienstag JL.

Adv Health Sci Educ Theory Pract. 2017 Mar;22(1):5-15. doi: 10.1007/s10459-016-9678-5. Epub 2016 Apr 25.

11.

Medical Students Who Pursue a Joint MD/MBA Degree: Who Are They and Where Are They Heading?

Krupat E, Dienstag JL, Kester WC, Finkelstein SN.

Eval Health Prof. 2017 Jun;40(2):203-218. doi: 10.1177/0163278715620831. Epub 2016 Jan 21.

PMID:
26801747
12.

Processes to manage analyses and publications in a phase III multicenter randomized clinical trial.

Snow KK, Bell MC, Stoddard AM, Curto TM, Wright EC, Dienstag JL.

Trials. 2014 May 7;15:159. doi: 10.1186/1745-6215-15-159.

13.

In reply to Alexander et al.

Leape L, Shore M, Dienstag JL.

Acad Med. 2013 Jun;88(6):741-2. doi: 10.1097/ACM.0b013e318290b63c. No abstract available.

PMID:
23708592
14.

Liver transplantation--a vision realized.

Dienstag JL, Cosimi AB.

N Engl J Med. 2012 Oct 18;367(16):1483-5. doi: 10.1056/NEJMp1210159. Epub 2012 Sep 19. No abstract available.

PMID:
22992048
15.

The case for the new MCAT.

Dienstag JL.

N Engl J Med. 2012 Jul 19;367(3):280-1; author reply 281-2. doi: 10.1056/NEJMc1206331. No abstract available.

PMID:
22808979
16.

Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C.

Morishima C, Shiffman ML, Dienstag JL, Lindsay KL, Szabo G, Everson GT, Lok AS, Di Bisceglie AM, Ghany MG, Naishadham D, Morgan TR, Wright EC; HALT-C Trial Group.

Am J Gastroenterol. 2012 Sep;107(9):1388-98. doi: 10.1038/ajg.2012.137. Epub 2012 Jun 12.

17.

Perspective: a culture of respect, part 2: creating a culture of respect.

Leape LL, Shore MF, Dienstag JL, Mayer RJ, Edgman-Levitan S, Meyer GS, Healy GB.

Acad Med. 2012 Jul;87(7):853-8. doi: 10.1097/ACM.0b013e3182583536.

PMID:
22622219
18.

Perspective: a culture of respect, part 1: the nature and causes of disrespectful behavior by physicians.

Leape LL, Shore MF, Dienstag JL, Mayer RJ, Edgman-Levitan S, Meyer GS, Healy GB.

Acad Med. 2012 Jul;87(7):845-52. doi: 10.1097/ACM.0b013e318258338d.

PMID:
22622217
19.

Serum vitamin D levels are not predictive of the progression of chronic liver disease in hepatitis C patients with advanced fibrosis.

Corey KE, Zheng H, Mendez-Navarro J, Delgado-Borrego A, Dienstag JL, Chung RT; HALT-C Trial Group.

PLoS One. 2012;7(2):e27144. doi: 10.1371/journal.pone.0027144. Epub 2012 Feb 16.

20.

The Medical College Admission Test--toward a new balance.

Dienstag JL.

N Engl J Med. 2011 Nov 24;365(21):1955-7. doi: 10.1056/NEJMp1110171. No abstract available.

PMID:
22111717
21.

YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C.

Fontana RJ, Litman HJ, Dienstag JL, Bonkovsky HL, Su G, Sterling RK, Lok AS; HALT-C Trial Group.

Liver Int. 2012 Apr;32(4):665-74. doi: 10.1111/j.1478-3231.2011.02686.x. Epub 2011 Nov 22.

22.

Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C.

Sterling RK, Wright EC, Morgan TR, Seeff LB, Hoefs JC, Di Bisceglie AM, Dienstag JL, Lok AS.

Am J Gastroenterol. 2012 Jan;107(1):64-74. doi: 10.1038/ajg.2011.312. Epub 2011 Sep 20.

23.

Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C Trial.

Hoefs JC, Shiffman ML, Goodman ZD, Kleiner DE, Dienstag JL, Stoddard AM; HALT-C Trial Group.

Gastroenterology. 2011 Sep;141(3):900-908.e1-2. doi: 10.1053/j.gastro.2011.06.007. Epub 2011 Jun 12.

24.

A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C.

Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, Seeff LB, Szabo G, Wright EC, Sterling RK, Everson GT, Lindsay KL, Lee WM, Lok AS, Morishima C, Stoddard AM, Everhart JE; HALT-C Trial Group.

Hepatology. 2011 Aug;54(2):396-405. doi: 10.1002/hep.24370. Epub 2011 Jun 23.

25.

Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon.

Di Bisceglie AM, Stoddard AM, Dienstag JL, Shiffman ML, Seeff LB, Bonkovsky HL, Morishima C, Wright EC, Snow KK, Lee WM, Fontana RJ, Morgan TR, Ghany MG; HALT-C Trial Group.

Hepatology. 2011 Apr;53(4):1100-8. doi: 10.1002/hep.24169.

26.

A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma.

Abu Dayyeh BK, Yang M, Fuchs BC, Karl DL, Yamada S, Sninsky JJ, O'Brien TR, Dienstag JL, Tanabe KK, Chung RT; HALT-C Trial Group.

Gastroenterology. 2011 Jul;141(1):141-9. doi: 10.1053/j.gastro.2011.03.045. Epub 2011 Mar 24.

27.

Evolution of the New Pathway curriculum at Harvard Medical School: the new integrated curriculum.

Dienstag JL.

Perspect Biol Med. 2011 Winter;54(1):36-54. doi: 10.1353/pbm.2011.0003.

PMID:
21399382
28.

The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C Trial cohort.

Abu Dayyeh BK, Yang M, Dienstag JL, Chung RT.

Dig Dis Sci. 2011 Feb;56(2):564-8. doi: 10.1007/s10620-010-1507-8. Epub 2010 Dec 7.

29.

Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C.

Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Morgan TR; HALT-C Trial Group.

Gastroenterology. 2011 Mar;140(3):840-9; quiz e12. doi: 10.1053/j.gastro.2010.11.050. Epub 2010 Dec 1.

30.

Harvard Medical School.

Dienstag JL, Neill JM.

Acad Med. 2010 Sep;85(9 Suppl):S269-73. doi: 10.1097/ACM.0b013e3181e913e0. No abstract available.

PMID:
20736566
31.

Peginterferon therapy for HBeAg-negative chronic hepatitis B: less than meets the eye.

Dienstag JL.

Am J Gastroenterol. 2010 Aug;105(8):1770-2. doi: 10.1038/ajg.2010.187.

PMID:
20686463
32.

Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C.

Fontana RJ, Dienstag JL, Bonkovsky HL, Sterling RK, Naishadham D, Goodman ZD, Lok AS, Wright EC, Su GL; HALT-C Trial Group.

Gut. 2010 Oct;59(10):1401-9. doi: 10.1136/gut.2010.207423. Epub 2010 Jul 30.

33.

Outcome of sustained virological responders with histologically advanced chronic hepatitis C.

Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Dienstag JL, Morishima C, Lindsay KL, Lok AS; HALT-C Trial Group.

Hepatology. 2010 Sep;52(3):833-44. doi: 10.1002/hep.23744.

34.

Recommendations for prevention, screening, and diagnosis of HBV and HCV infections.

Peters MG, Weinbaum C, Tan L, Baine WB, Dienstag JL, Liang TJ, So S.

J Fam Pract. 2010 Apr;59(4 Suppl):S29-35. No abstract available.

PMID:
20398588
35.

Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial.

Seeff LB, Everson GT, Morgan TR, Curto TM, Lee WM, Ghany MG, Shiffman ML, Fontana RJ, Di Bisceglie AM, Bonkovsky HL, Dienstag JL; HALT–C Trial Group.

Clin Gastroenterol Hepatol. 2010 Oct;8(10):877-83. doi: 10.1016/j.cgh.2010.03.025. Epub 2010 Apr 1.

36.

Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial.

Everhart JE, Wright EC, Goodman ZD, Dienstag JL, Hoefs JC, Kleiner DE, Ghany MG, Mills AS, Nash SR, Govindarajan S, Rogers TE, Greenson JK, Brunt EM, Bonkovsky HL, Morishima C, Litman HJ; HALT-C Trial Group.

Hepatology. 2010 Feb;51(2):585-94. doi: 10.1002/hep.23315.

37.

Changes in quality of life and sexual health are associated with low-dose peginterferon therapy and disease progression in patients with chronic hepatitis C.

Snow KK, Bonkovsky HL, Fontana RJ, Kim HY, Sterling RK, Di Bisceglie AM, Morgan TR, Dienstag JL, Ghany MG; HALT-C Trial Group.

Aliment Pharmacol Ther. 2010 Apr;31(7):719-34. doi: 10.1111/j.1365-2036.2010.04235.x. Epub 2010 Jan 12.

38.

Perspective: Medical school admissions and noncognitive testing: some open questions.

Bardes CL, Best PC, Kremer SJ, Dienstag JL.

Acad Med. 2009 Oct;84(10):1360-3. doi: 10.1097/ACM.0b013e3181b6a6b3.

PMID:
19881422
39.

Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma.

Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, Morgan TR, Kim HY, Lee WM, Bonkovsky HL, Dienstag JL; HALT-C Trial Group.

Gastroenterology. 2010 Feb;138(2):493-502. doi: 10.1053/j.gastro.2009.10.031. Epub 2009 Oct 20.

40.

Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial.

Goodman ZD, Stoddard AM, Bonkovsky HL, Fontana RJ, Ghany MG, Morgan TR, Wright EC, Brunt EM, Kleiner DE, Shiffman ML, Everson GT, Lindsay KL, Dienstag JL, Morishima C; HALT-C Trial Group.

Hepatology. 2009 Dec;50(6):1738-49. doi: 10.1002/hep.23211.

41.

Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C.

Ghany MG, Lok AS, Everhart JE, Everson GT, Lee WM, Curto TM, Wright EC, Stoddard AM, Sterling RK, Di Bisceglie AM, Bonkovsky HL, Morishima C, Morgan TR, Dienstag JL; HALT-C Trial Group.

Gastroenterology. 2010 Jan;138(1):136-46. doi: 10.1053/j.gastro.2009.09.007. Epub 2009 Sep 18.

42.

Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial.

Shiffman ML, Morishima C, Dienstag JL, Lindsay KL, Hoefs JC, Lee WM, Wright EC, Naishadham D, Everson GT, Lok AS, Di Bisceglie AM, Bonkovsky HL, Ghany MG; HALT-C Trial Group.

Gastroenterology. 2009 Dec;137(6):1986-94. doi: 10.1053/j.gastro.2009.08.067. Epub 2009 Sep 10. Erratum in: Gastroenterology. 2010 Mar;138(3):1215.

43.

Pilot study of postexposure prophylaxis for hepatitis C virus in healthcare workers.

Corey KE, Servoss JC, Casson DR, Kim AY, Robbins GK, Franzini J, Twitchell K, Loomis SC, Abraczinskas DR, Terella AM, Dienstag JL, Chung RT.

Infect Control Hosp Epidemiol. 2009 Oct;30(10):1000-5. doi: 10.1086/605718.

44.

Commentary: Assessment is an educational tool.

Krupat E, Dienstag JL.

Acad Med. 2009 May;84(5):548-50. doi: 10.1097/ACM.0b013e31819f7fb9.

PMID:
19704183
45.

Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C.

Freedman ND, Everhart JE, Lindsay KL, Ghany MG, Curto TM, Shiffman ML, Lee WM, Lok AS, Di Bisceglie AM, Bonkovsky HL, Hoefs JC, Dienstag JL, Morishima C, Abnet CC, Sinha R; HALT-C Trial Group.

Hepatology. 2009 Nov;50(5):1360-9. doi: 10.1002/hep.23162.

46.

Benefits and risks of nucleoside analog therapy for hepatitis B.

Dienstag JL.

Hepatology. 2009 May;49(5 Suppl):S112-21. doi: 10.1002/hep.22920.

PMID:
19399795
47.

Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis.

Fontana RJ, Bonkovsky HL, Naishadham D, Dienstag JL, Sterling RK, Lok AS, Su GL; Halt-C Trial Group.

Clin Gastroenterol Hepatol. 2009 Feb;7(2):219-26. doi: 10.1016/j.cgh.2008.10.034. Epub 2008 Nov 7.

48.

Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.

Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, Lee WM, Lok AS, Bonkovsky HL, Morgan TR, Ghany MG, Morishima C, Snow KK, Dienstag JL; HALT-C Trial Investigators.

N Engl J Med. 2008 Dec 4;359(23):2429-41. doi: 10.1056/NEJMoa0707615.

49.

Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease.

Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Goodman ZD; HALT-C Trial Group.

Gastroenterology. 2009 Jan;136(1):138-48. doi: 10.1053/j.gastro.2008.09.014. Epub 2008 Sep 18.

50.

Hepatitis B virus infection.

Dienstag JL.

N Engl J Med. 2008 Oct 2;359(14):1486-500. doi: 10.1056/NEJMra0801644. Review. No abstract available. Erratum in: N Engl J Med. 2010 Jul 15;363(3):298.

PMID:
18832247

Supplemental Content

Loading ...
Support Center